# Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI Treatment: a Prospective, Single Arm, Phase II Clinical Study

> **NCT07488572** · PHASE2 · ENROLLING_BY_INVITATION · sponsor: **Sun Yat-sen University** · enrollment: 60 (estimated)

## Conditions studied

- Renal Cell Carcinoma (RCC)
- Metastatic Clear Cell Renal Cell Carcinoma

## Interventions

- **DRUG:** Yivoximab

## Key facts

- **NCT ID:** NCT07488572
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ENROLLING_BY_INVITATION
- **Start date:** 2025-11-01
- **Primary completion:** 2027-06-01
- **Final completion:** 2027-06-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2026-03-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07488572

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07488572, "Safety and Efficacy of Yiwoxidan Anti (AK112) Monotherapy in Patients With Metastatic Renal Clear Cell Carcinoma Who Are Intolerant to TKI Treatment: a Prospective, Single Arm, Phase II Clinical Study". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT07488572. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*